Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01437657 · ClinicalTrials.gov registry record · Phase 2
MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 319
- Enrollment target
NCT01437657 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 319 participants.
The verdict
NCT01437657, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 319 participants
- Enrollment target
Study Summary
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the safety and efficacy of RO4917523 as adjunctive therapy in patients with major depressive disorder and an inadequate response to ongoing antidepressant therapy. Anticipated time on study treatment is 6 weeks with a 3-week follow-up.
Interventions
- DRUG Placebo
- DRUG RO4917523 0.5 mg
- DRUG RO4917523 1.5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 319 participants |
| Start Date | 2011-10 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01437657
The ClinicalTrials.gov registry entry for NCT01437657 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 319 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01437657 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01437657 about?
NCT01437657 is a clinical study titled "MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy". This randomized, double-blind, placebo-controlled, parallel group study will evaluate the safety and efficacy of RO4917523 as adjunctive therapy in patients with major depressive disorder and an inadequate response to ongoing antidepressant therapy. Anticipated time on study treatment is 6 weeks wit...
What is the current status of trial NCT01437657?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 319 participants. The study started on 2011-10. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01437657?
The interventions under investigation include: Placebo (DRUG), RO4917523 0.5 mg (DRUG), RO4917523 1.5 mg (DRUG).
Who is sponsoring clinical trial NCT01437657?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.